Prognostic value of NT-proBNP in heart failure with preserved versus reduced EF

on behalf of the KorHF Registry

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Objective: Plasma level of N-terminal-pro-brain natriuretic peptide (NT-proBNP) is a reliable prognostic factor in patients with heart failure (HF). However, it is unclear how differently the biomarker predicts adverse outcomes in HF with preserved EF (HFpEF) versus HF with reduced EF (HFrEF). Methods: From the Korean Heart Failure registry, a prospective multicentre cohort for consecutive patients who were hospitalised for acute HF syndrome, those with available NT-proBNP and LVEF measurements were extracted. Patients with LVEF ≥50% were categorised as the HFpEF group (N=528) and those with ≤40% as the HFrEF group (N=1142). Results: Patients with HFpEF had significantly lower NT-proBNP level than those with HFrEF (median 2723 vs 5644 ng/L, p<0.001). Event-free survival did not differ between the two groups either in terms of death from any cause (88.4% vs 86.9%; p=0.471) or the composite of death or HF readmission at 1 year (73.8% vs 70.6%; p=0.225). High levels of NT-proBNP were significantly associated with poor outcomes. However, the relationship was not different among the HFpEF and HFrEF groups (interaction p=0.956 for all-cause death; p=0.351 for the composite of all-cause death or HF hospitalisation). Conclusions: Plasma level of NT-proBNP is the most powerful prognostic factor in both HFpEF and HFrEF. Although patients with HFpEF have lower NT-proBNP levels, the prognosis of a patient with HFpEF expected from a given NT-proBNP level is similar with his/her counterpart with HFrEF.

Original languageEnglish
Pages (from-to)1881-1888
Number of pages8
JournalHeart
Volume101
Issue number23
DOIs
Publication statusPublished - 2015 Dec 1

Fingerprint

Brain Natriuretic Peptide
Heart Failure
Cause of Death
Disease-Free Survival
Registries
Hospitalization
Biomarkers

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

on behalf of the KorHF Registry. / Prognostic value of NT-proBNP in heart failure with preserved versus reduced EF. In: Heart. 2015 ; Vol. 101, No. 23. pp. 1881-1888.
@article{002a0f1dec1b4998a3c5381be44fac1a,
title = "Prognostic value of NT-proBNP in heart failure with preserved versus reduced EF",
abstract = "Objective: Plasma level of N-terminal-pro-brain natriuretic peptide (NT-proBNP) is a reliable prognostic factor in patients with heart failure (HF). However, it is unclear how differently the biomarker predicts adverse outcomes in HF with preserved EF (HFpEF) versus HF with reduced EF (HFrEF). Methods: From the Korean Heart Failure registry, a prospective multicentre cohort for consecutive patients who were hospitalised for acute HF syndrome, those with available NT-proBNP and LVEF measurements were extracted. Patients with LVEF ≥50{\%} were categorised as the HFpEF group (N=528) and those with ≤40{\%} as the HFrEF group (N=1142). Results: Patients with HFpEF had significantly lower NT-proBNP level than those with HFrEF (median 2723 vs 5644 ng/L, p<0.001). Event-free survival did not differ between the two groups either in terms of death from any cause (88.4{\%} vs 86.9{\%}; p=0.471) or the composite of death or HF readmission at 1 year (73.8{\%} vs 70.6{\%}; p=0.225). High levels of NT-proBNP were significantly associated with poor outcomes. However, the relationship was not different among the HFpEF and HFrEF groups (interaction p=0.956 for all-cause death; p=0.351 for the composite of all-cause death or HF hospitalisation). Conclusions: Plasma level of NT-proBNP is the most powerful prognostic factor in both HFpEF and HFrEF. Although patients with HFpEF have lower NT-proBNP levels, the prognosis of a patient with HFpEF expected from a given NT-proBNP level is similar with his/her counterpart with HFrEF.",
author = "{on behalf of the KorHF Registry} and Kang, {Si Hyuck} and Park, {Jin Joo} and Choi, {Dong Ju} and Yoon, {Chang Hwan} and Oh, {Il Young} and seokmin kang and Byungsu Yoo and Jeon, {Eun Seok} and Kim, {Jae Joong} and Cho, {Myeong Chan} and Chae, {Shung Chull} and Ryu, {Kyu Hyung} and Oh, {Byung Hee}",
year = "2015",
month = "12",
day = "1",
doi = "10.1136/heartjnl-2015-307782",
language = "English",
volume = "101",
pages = "1881--1888",
journal = "Heart",
issn = "1355-6037",
publisher = "BMJ Publishing Group",
number = "23",

}

Prognostic value of NT-proBNP in heart failure with preserved versus reduced EF. / on behalf of the KorHF Registry.

In: Heart, Vol. 101, No. 23, 01.12.2015, p. 1881-1888.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prognostic value of NT-proBNP in heart failure with preserved versus reduced EF

AU - on behalf of the KorHF Registry

AU - Kang, Si Hyuck

AU - Park, Jin Joo

AU - Choi, Dong Ju

AU - Yoon, Chang Hwan

AU - Oh, Il Young

AU - kang, seokmin

AU - Yoo, Byungsu

AU - Jeon, Eun Seok

AU - Kim, Jae Joong

AU - Cho, Myeong Chan

AU - Chae, Shung Chull

AU - Ryu, Kyu Hyung

AU - Oh, Byung Hee

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Objective: Plasma level of N-terminal-pro-brain natriuretic peptide (NT-proBNP) is a reliable prognostic factor in patients with heart failure (HF). However, it is unclear how differently the biomarker predicts adverse outcomes in HF with preserved EF (HFpEF) versus HF with reduced EF (HFrEF). Methods: From the Korean Heart Failure registry, a prospective multicentre cohort for consecutive patients who were hospitalised for acute HF syndrome, those with available NT-proBNP and LVEF measurements were extracted. Patients with LVEF ≥50% were categorised as the HFpEF group (N=528) and those with ≤40% as the HFrEF group (N=1142). Results: Patients with HFpEF had significantly lower NT-proBNP level than those with HFrEF (median 2723 vs 5644 ng/L, p<0.001). Event-free survival did not differ between the two groups either in terms of death from any cause (88.4% vs 86.9%; p=0.471) or the composite of death or HF readmission at 1 year (73.8% vs 70.6%; p=0.225). High levels of NT-proBNP were significantly associated with poor outcomes. However, the relationship was not different among the HFpEF and HFrEF groups (interaction p=0.956 for all-cause death; p=0.351 for the composite of all-cause death or HF hospitalisation). Conclusions: Plasma level of NT-proBNP is the most powerful prognostic factor in both HFpEF and HFrEF. Although patients with HFpEF have lower NT-proBNP levels, the prognosis of a patient with HFpEF expected from a given NT-proBNP level is similar with his/her counterpart with HFrEF.

AB - Objective: Plasma level of N-terminal-pro-brain natriuretic peptide (NT-proBNP) is a reliable prognostic factor in patients with heart failure (HF). However, it is unclear how differently the biomarker predicts adverse outcomes in HF with preserved EF (HFpEF) versus HF with reduced EF (HFrEF). Methods: From the Korean Heart Failure registry, a prospective multicentre cohort for consecutive patients who were hospitalised for acute HF syndrome, those with available NT-proBNP and LVEF measurements were extracted. Patients with LVEF ≥50% were categorised as the HFpEF group (N=528) and those with ≤40% as the HFrEF group (N=1142). Results: Patients with HFpEF had significantly lower NT-proBNP level than those with HFrEF (median 2723 vs 5644 ng/L, p<0.001). Event-free survival did not differ between the two groups either in terms of death from any cause (88.4% vs 86.9%; p=0.471) or the composite of death or HF readmission at 1 year (73.8% vs 70.6%; p=0.225). High levels of NT-proBNP were significantly associated with poor outcomes. However, the relationship was not different among the HFpEF and HFrEF groups (interaction p=0.956 for all-cause death; p=0.351 for the composite of all-cause death or HF hospitalisation). Conclusions: Plasma level of NT-proBNP is the most powerful prognostic factor in both HFpEF and HFrEF. Although patients with HFpEF have lower NT-proBNP levels, the prognosis of a patient with HFpEF expected from a given NT-proBNP level is similar with his/her counterpart with HFrEF.

UR - http://www.scopus.com/inward/record.url?scp=84948720562&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948720562&partnerID=8YFLogxK

U2 - 10.1136/heartjnl-2015-307782

DO - 10.1136/heartjnl-2015-307782

M3 - Article

VL - 101

SP - 1881

EP - 1888

JO - Heart

JF - Heart

SN - 1355-6037

IS - 23

ER -